Personalizing risk stratification by addition of PAK1 expression to TNM staging: Improving the accuracy of clinical decision for gastroesophageal junction adenocarcinoma-Reference-Cited by-同舟云学术

Personalizing risk stratification by addition of PAK1 expression to TNM staging: Improving the accuracy of clinical decision for gastroesophageal junction adenocarcinoma

Published:2014-09-04 Issue:7 Volume:136 Page:1636-1645
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Li Zongtai¹²³,Zou Xiaofang¹³,Xie Liangxi⁴,Chen Hongcai¹³,Chen Yuping⁵,Yeung Sai-Ching Jim⁶⁷,Zhang Hao¹³⁸

Affiliation:

1. Department of Biotherapy and Gastrointestinal Medical Oncology; Affiliated Cancer Hospital of Shantou University Medical College; Shantou China

2. Department of Oncological Radiotherapy; The People's Hospital of Gaozhou; Gaozhou Guangdong China

3. Cancer Research Center; Shantou University Medical College; Shantou China

4. Department of Radiation Oncology; Affiliated Cancer Hospital of Shantou University Medical College; Shantou China

5. Department of Thoraticic Surgery; Affiliated Cancer Hospital of Shantou University Medical College; Shantou China

6. Department of Endocrine Neoplasia and Hormonal Disorders; The University of Texas MD Anderson Cancer Center; Houston TX

7. Department of Emergency Medicine; The University of Texas MD Anderson Cancer Center; Houston TX

8. Tumor Tissue Bank; Affiliated Cancer Hospital of Shantou University Medical College; Shantou China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference44 articles.

1. Esophageal and gastric cardia cancers on 4238 Chinese patients residing in municipal and rural regions: a histopathological comparison during 24-year period;Fan;World J Surg,2008

2. Multidisciplinary management of gastric and gastroesophageal cancers;Moehler;World J Gastroenterol,2008

3. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence;Pohl;J Natl Cancer Inst,2005

4. Fate of patients with adenocarcinoma of the esophagus and the esophagogastric junction: a population-based analysis;Sihvo;Am J Gastroenterol,2004

5. Classification of adenocarcinoma of the oesophagogastric junction;Siewert;Br J Surg,1998

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kinetics of plasma cell-free DNA as a prospective biomarker to predict the prognosis and radiotherapy effect of esophageal cancer;Cancer/Radiothérapie;2024-06

2. Targeting PAK4 reverses cisplatin resistance in NSCLC by modulating ER stress;Cell Death Discovery;2024-01-18

3. Construction and validation of nomograms to predict overall survival and cancer-specific survival in patients with gastroesophageal junction cancer of no distant metastasis;2023-07-31

4. Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma;World Journal of Surgical Oncology;2022-07-16

5. The oncogenic roles of nuclear receptor coactivator 1 in human esophageal carcinoma;Cancer Medicine;2018-09-30